Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Meta Expands AI Training With Employee Activity Tracking Tools 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
EXTON, Pa., March 03, 2016 -- Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing transformational therapies for diseases affecting the skin, connective tissue and joints, will report financial results for the fourth quarter and year ended December 31, 2015 and recent operational highlights on Thursday, March 10, 2016, before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EST on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks.
To participate on the live call, please dial 855-877-0343 (domestic) or +1-678-509-8772 (international), and provide the conference code 47056115 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call. Please visit Fibrocell's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell’s most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for diseases of the skin, connective tissue and joints using genetically-modified autologous fibroblasts. Fibrocell is in pre-clinical development of FCX-007, its orphan gene-therapy product candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in pre-clinical development of FCX-013, its gene-therapy product candidate for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon are in collaboration to develop a gene therapy for the treatment of arthritis. For more information, visit www.fibrocell.com.
Investor Relations Contact: John Woolford Westwicke Partners 443.213.0506 [email protected] Media Relations Contact: Michael Parks 484.356.7105 [email protected]
